找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Chronic Lymphocytic Leukemia; Michael Hallek,Barbara Eichhorst,Daniel Catovsky Book 2019 Springer Nature Switzerland AG 2019 Chronic Lymph

[復(fù)制鏈接]
查看: 38319|回復(fù): 54
樓主
發(fā)表于 2025-3-21 19:02:06 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Chronic Lymphocytic Leukemia
編輯Michael Hallek,Barbara Eichhorst,Daniel Catovsky
視頻videohttp://file.papertrans.cn/227/226394/226394.mp4
概述Summarizes current knowledge on all aspects of CLL.Describes the role of different diagnostic procedures.Examines the changing treatment paradigm in CLL and the emergence of new therapeutic targets.Eq
叢書名稱Hematologic Malignancies
圖書封面Titlebook: Chronic Lymphocytic Leukemia;  Michael Hallek,Barbara Eichhorst,Daniel Catovsky Book 2019 Springer Nature Switzerland AG 2019 Chronic Lymph
描述.This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapyof T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed...?.
出版日期Book 2019
關(guān)鍵詞Chronic Lymphocytic Leukemia; Pathophysiology; Prognosis; Treatment; T-cell prolymphocytic leukemia; T-ce
版次1
doihttps://doi.org/10.1007/978-3-030-11392-6
isbn_ebook978-3-030-11392-6Series ISSN 2197-9766 Series E-ISSN 2197-9774
issn_series 2197-9766
copyrightSpringer Nature Switzerland AG 2019
The information of publication is updating

書目名稱Chronic Lymphocytic Leukemia影響因子(影響力)




書目名稱Chronic Lymphocytic Leukemia影響因子(影響力)學(xué)科排名




書目名稱Chronic Lymphocytic Leukemia網(wǎng)絡(luò)公開(kāi)度




書目名稱Chronic Lymphocytic Leukemia網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Chronic Lymphocytic Leukemia被引頻次




書目名稱Chronic Lymphocytic Leukemia被引頻次學(xué)科排名




書目名稱Chronic Lymphocytic Leukemia年度引用




書目名稱Chronic Lymphocytic Leukemia年度引用學(xué)科排名




書目名稱Chronic Lymphocytic Leukemia讀者反饋




書目名稱Chronic Lymphocytic Leukemia讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:08:27 | 只看該作者
板凳
發(fā)表于 2025-3-22 03:14:17 | 只看該作者
The Clinical Presentation of CLLedominantly a disease of the elderly with a preponderance of male patients. New evidence suggests that there are variations in gender incidence according to the clinical status of patients, with a higher male:female ratio in the groups with worse prognosis..Full blood counts and a physical examinati
地板
發(fā)表于 2025-3-22 05:08:43 | 只看該作者
5#
發(fā)表于 2025-3-22 10:59:38 | 只看該作者
Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management road acceptance by physicians and investigators caring for patients with CLL. It is not the aim of the iwCLL guidelines to provide treatment recommendations, but definitions for the initial assessment, indication for treatment, and response assessment of CLL. Recent advances including the discovery
6#
發(fā)表于 2025-3-22 16:50:43 | 只看該作者
Initial Therapy of Chronic Lymphocytic Leukemiaients without very high-risk genomic alterations first-line treatment with chemoimmunotherapy is a well-examined and established standard of care. FCR is the preferred treatment in physically fit patients with mild or no comorbidities. Depending on the burden of comorbidities, less intense chemoimmu
7#
發(fā)表于 2025-3-22 20:01:51 | 只看該作者
8#
發(fā)表于 2025-3-22 23:24:54 | 只看該作者
9#
發(fā)表于 2025-3-23 03:14:33 | 只看該作者
Autoimmune Cytopenia in Chronic Lymphocytic Leukemiauses, patients with CLL presenting cytopenia require a careful evaluation and an individualized management. The association of CLL with cytopenias of immune origin is based on experts’ consensus, and its impact on patients’ outcome remains controversial. It is widely accepted that treatment should b
10#
發(fā)表于 2025-3-23 08:19:11 | 只看該作者
Richter Syndromeare recognized, namely the diffuse large B-cell lymphoma (DLBCL) variant and the rare Hodgkin lymphoma (HL) variant. Histologic documentation is mandatory to diagnose RS. In the presence of clinical features suspicious of RS, diagnosis of transformation and choice of the site of biopsy may take adva
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 18:31
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
台北市| 鸡泽县| 新龙县| 板桥市| 会理县| 潼南县| 博野县| 湘潭市| 西城区| 邵阳市| 清涧县| 麻江县| 玛纳斯县| 柳林县| 九龙县| 龙泉市| 青川县| 东丽区| 南康市| 小金县| 岗巴县| 山阳县| 南康市| 晋宁县| 修文县| 道真| 西峡县| 鄢陵县| 兴文县| 丹凤县| 鄯善县| 曲阳县| 定襄县| 文成县| 南充市| 六安市| 金阳县| 曲周县| 鄢陵县| 缙云县| 明星|